RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease Nov 21, 2022
NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM) Nov 18, 2022
NeoGenomics Appoints David Perez, Industry Veteran and Former Terumo BCT CEO, to Its Board of Directors Nov 7, 2022
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022 Sep 7, 2022
